However, one of the key strengths of this population-based study is that all patients who were diagnosed with T1a or T1b HER2-positive breast cancer in the province of Saskatchewan were evaluated, and there was no selection bias or loss to follow-up. This evidence concerns the gene ERBB2 and breast cancer.